![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR... Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company's only operating segment is developing and commercializing genome editing technology. Show more
On track to present additional clinical data from the RUBY trial and the EdiTHAL trial by year-end In vivo preclinical proof-of-concept for an undisclosed indication on-track by year-end Strong...
CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast...
All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization of total hemoglobin with a mean...
All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel) infusion Reni-cel was...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1301 | -3.25241868953 | 4.0001 | 4.19 | 3.77 | 1437784 | 3.99593172 | CS |
4 | -1.85 | -32.3426573427 | 5.72 | 5.85 | 3.71 | 1590387 | 4.4244454 | CS |
12 | -1.32 | -25.4335260116 | 5.19 | 6.22 | 3.71 | 1978500 | 4.98969007 | CS |
26 | -4.02 | -50.9505703422 | 7.89 | 11.58 | 3.71 | 1991947 | 6.13803325 | CS |
52 | -4.94 | -56.0726447219 | 8.81 | 11.69 | 3.71 | 1840826 | 7.30008882 | CS |
156 | -61.17 | -94.0498154982 | 65.04 | 73.025 | 3.71 | 1781963 | 13.76335336 | CS |
260 | -21.29 | -84.6184419714 | 25.16 | 99.95 | 3.71 | 1614222 | 24.02301644 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions